Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Infectious DNA as a vaccine against west nile and other flavivirues

a technology of infectious dna and vaccine, which is applied in the field of infectious dna as a vaccine against west nile and other flavivirues, can solve the problems of affecting the development affecting the ability of live attenuated west nile vaccine to elicit balanced humoral and cell-mediated immune responses, and imposing a substantial economic burden. , to achieve the effect of reducing the risk of infection,

Inactive Publication Date: 2005-12-15
UNIVERSITY OF KANSAS
View PDF0 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0010] Still another object of the present invention is to provide plasmid DNA encoding for an (+) RNA viral genome, which can be amplified in E. coli and easily prepared in large amounts.
[0011] Another object of the present invention is to use DNA immunization methodology for direct vaccination using infectious DNA, which will provide a stable and safe vaccine for an (+) RNA virus with increased shelf life due to a higher stability of the purified DNA.
[0013] Another object of the present invention is to provide a flavivirus infectious DNA that is dichotomous nature such that it is partially protective against its own infectivity. Although in cell culture higher inputs of infectious DNA correspond to higher infection rate, this results in decreased mortality even for a highly virulent virus.

Problems solved by technology

Recent introduction of the virus into the naïve environment of the North American continent (Lanciotti et al., 1999) had disastrous consequences both for wildlife and human population (Roehrig et al., 2002) and in a few years has developed into a nationwide epidemiological problem.
In addition to hundreds of human mortality cases reported to the Centers for Disease Control (CDC, 2004), the virus imposes a substantial economical burden, especially on the equine industry (Anonymous, 2003).
However, development of a live attenuated West Nile vaccine, which may have a better capability to elicit balanced humoral and cell-mediated immune responses, is hindered by the high virulence and pathogenicity of the NY99 strain circulating in the U.S. (Beasley et al., 2002; Roehrig et al., 2002).
Unfortunately, difficulties are often encountered in the design of flavivirus infectious DNA.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Infectious DNA as a vaccine against west nile and other flavivirues
  • Infectious DNA as a vaccine against west nile and other flavivirues

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Infectious Clone of West Nile Virus

[0040] This example is set forth in Yamshchikov, An Infectious Clone of the West Nile Flavivirus, 1: Virology. 2001 Mar. 15;281(2):294-304, which is incorporated by reference in its entirety.

[0041] Cell Culture and Viruses

[0042] BHK-21 (Bredenbeek et al., 1993) and Vero (ATCC CRL-1586) cells were maintained at 37° C. in humidified atmosphere containing 5% CO2 in Dulbecco's modified Eagle medium (“DMEM”) supplemented with 5% fetal calf serum (“FCS”, Hyclone) and 13 antibiotic±antimycotic mixture (GIBCO-BRL). Aedes albopictus clone C6 / 36 (ATCC CRL-1660) cells were maintained at 28° C. in the same media supplemented with 10% FCS. The WN strain having ATCC Deposit No. ______ used in this study was recovered after electroporation of BHK cells with archival RNA isolated from virus WN956D1173B, which had been triply plaque-purified in Vero cells and grown in BHK cells (Wengler and Gross, 1978). The previous passage history of this virus ...

example 2

Isolation of WN 1415, a Molecular Clone of the 956D117B3 Virus

[0046] Isolate WN1415 used in this example was recovered after transfection of synthetic RNA prepared from the pSP6WN / Xba infectious clone (Yamshchikov et al., 2001) into BHK cells and was used at passage 2 in Vero cells.

[0047] For genetic characterization, total RNA was isolated from Vero cells infected with WN1415 at passage 2 after transfection. Direct sequencing of gel-purified cDNA fragments prepared from this RNA has revealed two silent substitutions in positions 4566 (C) and 8355 (U) of the WN1415 genome as compared to the reported nucleotide sequence of 956D117B3 (GenBank #M12294, which is incorporated by reference). No other differences were identified. The above substitutions, which are present in the infectious clone plasmid pWN14115 as well, likely constitute cDNA variants selected during cloning.

[0048] The nucleotide sequence of the parent 956D117B3 isolate at Vero passage 2 after its rescue from archival ...

example 3

Sequence Analysis of Parent B956 and its Descendants

[0049] This example investigated the extent of changes accumulated in the 956B117D3 genome over its passage history. In this example, the original B956 strain at mouse brain passage 2 was obtained from Dr. R. Shope (Galveston, Tex.). The B956 virus was passaged once in C6 / 36 cells and total RNA isolated from virus-infected cells was used for preparation of purified cDNA fragments.

[0050] Consensus sequencing (Pugachev et al., 2002) was done after reverse transcriptase polymerase chain reaction (“RT-PCR”) amplification of eight overlapping cDNA fragments spanning the entire genome of WN1415, 956D117B3 or B956 viruses using taq polymerase (Novagen). The gel-purified fragments were sequenced without intermediate subcloning steps using the ABI310 Genetic Analyzer (ABI, Foster City, Calif.). A set of sequencing primers was designed to provide overlapping sequence segments covering the entire genome in both directions based on GenBank #...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

A vaccine for West Nile virus that protects a subject against West Nile infection comprising an a pharmaceutically acceptable carrier and a therapeutically effective does of an infectious agent selected from the group consisting of: a live attenuated infectious (+) RNA virus designated as WN1415, a vector comprising infectious DNA encoding an infectious (+) RNA molecule encoding the West Nile virus, and the West Nile (+) RNA virus designated as WN956D117B3 (GenBank #M12294).

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] The present invention claims the benefit of provisional patent application No. 60 / 547,503, filed on Feb. 25, 2004, which is incorporated by reference in its entirety.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT [0002] The present invention was sponsored by the National Institute of Allergy and Infectious Disease Contracts No. A1049258 and A1052084 and World Health Organization V22 / 181 / 128, and the government may have certain rights in the invention.BACKGROUND OF THE INVENTION [0003] Flaviviruses are (+) RNA viruses that cause such diseases as West Nile fever (“WN”), dengue fever (“DEN”), yellow fever (“YF”), St. Louis encephalitis, Japanese encephalitis (“JE”), and tick-borne encephalitis (“TBE”). West Nile virus was first isolated over 60 years ago from the blood of a febrile patient (Smithburn et al., 1940), and is one of the most widespread flaviviruses worldwide. The virions of the West Nile fever virus are spheri...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/12C07K14/18C12N7/04
CPCA61K2039/5254A61K2039/53C12N2770/24161C12N7/00C12N2770/24122C07K14/005Y02A50/30
Inventor YAMSHCHIKOV, VLADIMIR F.
Owner UNIVERSITY OF KANSAS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com